drugset
Drugs / DCR-PHXC
last change Jul 2025 re-read 3 minutes ago

DCR-PHXC

also known as Nedosiran · Rivfloza
Developed for
primary hyperoxaluria type 1 · primary hyperoxaluria type 2 · primary hyperoxaluria type 3 · primary hyperoxaluria
Investigated by
Dicerna Pharmaceuticals, Inc. · Novo Nordisk A/S

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) RIVFLOZA — 2025-03-27 fda.gov ↗
Approved US (FDA) RIVFLOZA — 2023-09-29 fda.gov ↗

Trials 7

today
US approved 2023
NCT05001269 · Ph 2 NCT04580420 · Ph 2 NCT04555486 · Ph 1 NCT03847909 · Ph 2 NCT04042402 · Ph 3 NCT03392896 · Ph 1
201820192020202120222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04555486 Sep 2020 → Sep 2021 primary hyperoxaluria type 3 Dicerna Pharmaceuticals, Inc. Completed No outcome recorded
Phase 1 NCT03392896 Dec 2017 → Nov 2019 primary hyperoxaluria Dicerna Pharmaceuticals, Inc. Completed No outcome recorded
Phase 23 trials · 1 met primary
Phase 2 NCT05001269 Feb 2022 → Feb 2025 primary hyperoxaluria type 1, primary hyperoxaluria type 2, primary hyperoxaluria type 3 Dicerna Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT04580420 Apr 2021 → Dec 2031 expected end stage renal failure, primary hyperoxaluria type 1 Dicerna Pharmaceuticals, Inc. Recruiting No outcome recorded
Phase 2 NCT03847909 Oct 2019 → Jun 2021 kidney disorder, primary hyperoxaluria type 1, primary hyperoxaluria type 2 Novo Nordisk A/S Completed Met primary
Phase 31 trial
Phase 3 NCT04042402 Jul 2019 → Apr 2030 expected kidney disorder, primary hyperoxaluria type 1, primary hyperoxaluria type 2, primary hyperoxaluria type 3 Dicerna Pharmaceuticals, Inc. Active not recruiting No outcome recorded
Phase not stated1 trial
— NCT05993416 — primary hyperoxaluria type 1 Dicerna Pharmaceuticals, Inc. No longer available No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as DCR-PHXC ClinicalTrials.gov intervention name — accepted as the source's own label NCT04042402 ↗
4

NCT04580420 ↗

NCT03847909 ↗

NCT03392896 ↗

NCT04555486 ↗
Known as Nedosiran ClinicalTrials.gov intervention name — accepted as the source's own label NCT05993416 ↗
1

NCT05001269 ↗
Known as Rivfloza “Nedosiran (Rivfloza®) is an RNA interference (RNAi) therapy approved for individuals aged ≥ 2 years with primary hyperoxaluria type 1 (PH1)” PMID 40601241 ↗ Jul 2025
Action Inhibit “Nedosiran silences lactate dehydrogenase (LDH) mRNA in hepatocytes, reducing oxalate levels.” PMID 40601241 ↗ Jul 2025
Route Subcutaneous “DCR-PHXC is delivered via subcutaneous (SC) injection.” NCT03392896 ↗